Micaela Vagni

Medicine · Health Sciences

3h-index62citations17works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(15), DNA Repair Mechanisms(7), Cancer therapeutics and mechanisms(5), DNA and Nucleic Acid Chemistry(4), CAR-T cell therapy research(3)

Publications17 total

Supplementary Table 2 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplememntary Table 3 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Table 1 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Material and Methods from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Figures 1-8 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Data from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Figures 1-8 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Table 1 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Material and Methods from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Table 2 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Data from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplememntary Table 3 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
Molecular Cancer Therapeutics·2019· 35 citedOpen Access
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines
Targeted Oncology·2018· 7 cited
Inhibition of <scp>CHK</scp>1 and <scp>WEE</scp>1 as a new therapeutic approach in diffuse large B cell lymphomas with <scp>MYC</scp> deregulation
British Journal of Haematology·2016· 19 citedOpen Access
Inhibition of Chk1 and Wee1 as an effective therapeutic approach in diffuse large B cell lymphomas: A way to target Myc?
European Journal of Cancer·2016
Abstract C193: Combining ibrutinib with Chk1 inhibitors as a new therapeutic strategy for mantle cell lymphoma
Molecular Cancer Therapeutics·2015· 1 cited

Frequent Co-authors

Valentina Restelli(17), Giovanna Damia(17), Laura Carrassa(17), Monica Lupi(16), Francesco Bertoni(16), Rosaria Chilà(14), Chiara Tarantelli(13), Filippo Spriano(13), Eugenio Gaudio(13), Alberto J. Arribas(1)